Alpha-1 antitrypsin drugs: Key market research findings
- Alliances and strategic partnerships between vendors
- Improved diagnosis of AATD
Technavio has released a new market research report on the global alpha-1 antitrypsin drugs market, which is projected to reach almost $6 billion in market value by 2020. due to the increased awareness about the potential uses of alpha-1 antitrypsin therapeutics. At present, the Americas dominate the global alpha-1 antitrypsin drugs market and is expected to grow at a CAGR of around 35% over the forecast period. The increasing pervasiveness of people with alpha-1 antitrypsin deficiency (AATD) disorder, and hence, the increased demand for biological drugs is the major fueling factor for the growth of the alpha-1 antitrypsin drugs market in this region.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“Alliances formed in terms of collaboration or licensing is expected to help in the co-development and commercialization of drugs in various regions. Such partnerships make it possible to access the technical expertise of one another, and also ensure the inflow of adequate funds and reduce the cost of liability. Patient assistance programs offered to patients purchasing alpha-1 antitrypsin drugs is also expected to contribute to the growth of this market over the next four years,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
Various organizations are attempting to create awareness about AATD, which helps in recognizing and differentiating the condition from other diseases through different programs. For instance, the Alpha-1 Foundation organizes support programs which include Alpha-1 Kids, Genetic Counselling Program, Caregivers Support Group, and education days at different locations throughout the US and an annual National Education Conference. This improvement in terms of diagnosing AATD is projected to boost the market between 2016 and 2020.
The key vendors in the global alpha-1 antitrypsin drugs market are Baxter, CSL Behring, Grifols, and Kamada. The global alpha-1 antitrypsin drugs market is highly fragmented because of the presence of numerous small and large vendors. The high level of vendor competition in this market has led to an increase in the number of mergers and acquisitions, wherein smaller entities are being acquired by or are being merged with, major players.
A more detailed analysis is available in the market research report, Global Alpa-1 Antitrypsin Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
